South Korea Biosimilar Market Analysis

South Korea has emerged as one of the strategic location for the development of bi...
For Report Sample Contact: avinash@kuickresearch.com
Table Of Contents
1. South Korea Biosimilar Market Overview
1.1 Curre...
3.4 Pharmascience and Korea Kolmar Holdings

4. Emerging Trends
4.1 Government Investments in the Biosimilar Development
4...
6.5.2 Pharmacodynamic Studies
6.5.3 Efficacy Studies
6.5.4 Confirmatory Pharmacokinetic / Pharmacodynamic Studies
6.5.5 Sa...
List of Tables

Table 2-1: South Korea Biosimilar Pipeline by Disease, Phase & Company

Table 5-1: Bio Clusters in South K...
Upcoming SlideShare
Loading in...5
×

South korea biosimilar market analysis

76

Published on

“South Korea Biosimilar Market Analysis” reports gives comprehensive details on following aspects related to Biosimilar development in South Korea:
Market Overview
• Favorable Market Parameters
• Biosimilar Pipeline Analysis by Company, Phase & Disease
• Regulation foe Development of Biosimilars
• Emerging Market Trends
• Competitive Landscape
• Agreement & Partnership for Development of Biosimilars

For Report Sample Contact: avinash@kuickresearch.com

Published in: Health & Medicine, Travel
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
76
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

South korea biosimilar market analysis

  1. 1. South Korea Biosimilar Market Analysis South Korea has emerged as one of the strategic location for the development of biosimilars on the global level. Among the various emerging countries identified for development of biosimilars, South Korea is one of the most promising countries where pharmaceutical companies have identified huge investment potentials for the drug development process. One of the major reasons for the attractiveness of South Korea is the end of patent protection for some blockbuster drugs in the coming years and the need for novel therapeutics. Offering the advantages of favorable government and business conducive environment, the South Korean biosimilars market is poised for significant and rapid growth in the future years. There are many favorable steps undertaken by the government in this regard, some of them being tax holidays, tax concessions, cash grant, site location support and financial support for pharmaceutical companies investing in Korea. Thus, with all the government policies and frameworks, the biosimilars market in South Korea has become the growth engine of the country attracting huge investments from public and private companies located in and outside Korea. The South Korean Government has announced its plans to promote the biosimilars industry and make huge investments in the industry so as to make Korea a dominant player in the global marketplace. At present, the share of South Korea in the global biosimilars development is extremely meager. However, with the aggressive government support, and the increasing focus on biosimilars development, the government aims that the country would occupy a significant share of the global market for biosimilars by 2020. “South Korea Biosimilar Market Analysis” reports gives comprehensive details on following aspects related to Biosimilar development in South Korea: Market Overview • • • • • • Favorable Market Parameters Biosimilar Pipeline Analysis by Company, Phase & Disease Regulation foe Development of Biosimilars Emerging Market Trends Competitive Landscape Agreement & Partnership for Development of Biosimilars
  2. 2. For Report Sample Contact: avinash@kuickresearch.com Table Of Contents 1. South Korea Biosimilar Market Overview 1.1 Current Market Scenario 1.2 Favorable Market Dynamics for Development of Biosimilars 1.3 Challenges to be Resolved for Development of Biosimilars 2. South Korea Biosimilar Pipeline (Clinical Phase, Indication, Biochemical Class & Company) 2.1 Research 2.2 Preclinical 2.3 Phase-I 2.4 Phase-II 2.5 Phase-III 2.6 Preregistration 2.7 Registered 2.8 Marketed 3. Agreement & Partnership for Development of Biosimilars 3.1 Samsung Biologics & Biogen Idec 3.2 Merck & Hanwha Chemical Corporation 3.3 Meiji Seika Pharma and Dong-A Pharmaceutical
  3. 3. 3.4 Pharmascience and Korea Kolmar Holdings 4. Emerging Trends 4.1 Government Investments in the Biosimilar Development 4.2 Approval of first Biosimilar Drug of Arthritis Medicine by KFDA 4.3 Local Firms Dominating the Biosimilar R&D 4.4 Rising Bio Industry Exports 5. South Korea Biosimilar Market Future Outlook 5.1 Domestic Market Opportunity 5.2 Contract Manufacturing Opportunity 6. Regulation for Evaluation of Biosimilars in South Korea 6.1 Terminology 6.2 Selection Of Reference Product 6.3 Evaluation of Quality 6.3.1 Manufacturing Process 6.3.2 Comparability Studies For Quality Evaluation 6.3.3 Specifications 6.3.4 Analytical Procedures 6.3.5 Stability Studies 6.4 Non-Clinical Evaluation 6.5 Clinical Evaluation 6.5.1 Pharmacokinetic Studies
  4. 4. 6.5.2 Pharmacodynamic Studies 6.5.3 Efficacy Studies 6.5.4 Confirmatory Pharmacokinetic / Pharmacodynamic Studies 6.5.5 Safety 6.5.6 Immunogenicity 6.5.7 Extrapolation To Other Clinical Indications 7. Competitive Landscape 7.1 Samsung Biologics 7.2 Celltrion 7.3 Dong-A Pharm 7.4 LG life Sciences 7.5 ISU Abxis Figure 1-1: Biopharmaceutical Market (US$ Billion), 2008-2011 Figure 1-2: Share of South Korea in Global Biosimilar Market, 2012 Figure 1-3: South Korea Biosimilar Market Revenue (US$ Million), 2011-2013 Figure 1-4: Favorable Market Dynamics for Biosimilar Development in South Korea Figure 1-5: Key Challenges for Biosimilar Development in South Korea Figure 1-6: Regulatory Framework for Biosimilar Development in South Korea Figure 2-1: Number of Biosimilars Development by Phase Figure 2-2: Number of Biosimilars Development by Disease Figure 5-1: Targeted Share of South Korea in Global Biosimilar Market, 2020 Figure 5-2: South Korea Biosimilar Market Revenue Forecast (US$ Million), 2014-2018 Figure 5-3: Factors Driving Contract Manufacturing Opportunity in South Korea
  5. 5. List of Tables Table 2-1: South Korea Biosimilar Pipeline by Disease, Phase & Company Table 5-1: Bio Clusters in South Korea- Major Pockets of Opportunities in the Biosimilars Market Table 7-1: Celltrion Drug Pipeline Table 7-2: Dong-A Pharmaceutical Drug Pipeline

×